 |
|
|
| |
REAL-WORLD EFFECTIVENESS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A META-ANALYSIS
|
| |
| |
Reported by Jules Levin
Presented at EASL: The International Liver Congress - Vienna, Austria
13 April 2019
Markus Cornberg1, Francesco Negro2, Pietro Lampertico3, Juan Turnes4, Michael P. Curry5, Ashley Brown6, Heiner Wedemeyer7, Jose A. Carrion8, Nicole Wick9, Andreas Pangerl10, Eric Crown10, Lois Larsen10, Yao Yu10, Marcello Persico11
1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 2. Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, Geneva, Switzerland; 3. Fondazione IRCCS Ca' Granda, OspedaleMaggiore Policlinico, University of Milan, Milan, Italy; 4. Department of Gastroenterology and Hepatology, C.H.U. Pontevedra & IIS Galicia Sur, Spain; 5. Beth Israel Deaconess Medical Center, Boston, MA, USA; 6. Imperial College HealthcareNHS Trust, London, United Kingdom; 7. University Clinic Essen, Essen, Germany; 8. Liver Section, Gastroenterology Department, Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), UAB (UniversitatAutonomade Barcelona), Barcelona, Spain; 9. Trio Health, La Jolla, USA; 10. AbbVie Inc., North Chicago, IL, USA; 11. Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy
|
| |
|
|
|
|
|
